Researchers explored data from five different randomized controlled trials, publishing their analysis in the American Journal of Cardiology.

Explore our on-the-ground coverage of the first day of ACC.22.

Day 2 of ACC.22 was jam-packed with late-breaking clinical trials. Read our quick rundown of what researchers shared with the public for the very first time. 

Read our in-person coverage of the final day of ACC.22.

Joanna Chikwe, MD, founding chair of the department of cardiac surgery at Cedars-Sinai Hospital, compares transcatheter edge-to-edge repair (TEER) to mitral valve surgery for primary mitral regurgitation.

Another single-chamber leadless pacemaker has officially hit the market. 

The first-in-man study, completed by a team of cardiologists in China, included 10 patients presenting with HFpEF. 

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet. 

The increased risk of deep vein thrombosis lasts for up to three months, researchers found.